SG11201909520VA - Rna for treatment of autoimmune diseases - Google Patents
Rna for treatment of autoimmune diseasesInfo
- Publication number
- SG11201909520VA SG11201909520VA SG11201909520VA SG11201909520VA SG 11201909520V A SG11201909520V A SG 11201909520VA SG 11201909520V A SG11201909520V A SG 11201909520VA SG 11201909520V A SG11201909520V A SG 11201909520VA
- Authority
- SG
- Singapore
- Prior art keywords
- mainz
- international
- der
- rna
- pct
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I P0 I P C T omit OH Elm Him °ow° lII ow (10) International Publication Number WO 2018/189193 Al (51) International Patent Classification: A61K 39/00 (2006.01) A61P 37/00 (2006.01) A61K 48/00 (2006.01) (21) International Application Number: PCT/EP2018/059188 (22) International Filing Date: 10 April 2018 (10.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2017/058651 11 April 2017 (11.04.2017) EP (71) Applicants: BIONTECH RNA PHARMACEUTICALS GMBH [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE). TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEIN- NUTZIGE GMBH [DE/DE]; FreiligrathstraBe 12, 55131 Mainz (DE). UNIVERSITATSMEDIZIN DER JOHAN- NES GUTENBERG-UNIVERSITAT MAINZ [DE/DE]; LangenbeckstraBe 1, 55131 Mainz (DE). (72) Inventors: SAHIN, Ugur; c/o BioNTech AG, An der Goldgrube 12, 55131 Mainz (DE). KREITER, Sebast- ian; Niklas-Vogt-StraBe 3, 55131 Mainz (DE). KRIENKE, Christina; SilvanerstraBe 6, 55276 Dienheim (DE). PETSCHENKA, Jutta; Am Schinnergraben 37, 55129 Mainz (DE). KRANZ, Lena Mareen; FeldbergstraBe 28, 55118 Mainz (DE). DIKEN, Mustafa; Bert-Brecht-StraBe 5, 55128 Mainz (DE). (74) Agent: MULLER, Christian; ZSP Patentanwalte PartG mbB, Hansastr. 32, 80686 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 O \" (57) : The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic 0 agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases. (54) Title: RNA FOR TREATMENT OF AUTOIMMUNE DISEASES
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/058651 WO2018188730A1 (en) | 2017-04-11 | 2017-04-11 | Rna for treatment of autoimmune diseases |
| PCT/EP2018/059188 WO2018189193A1 (en) | 2017-04-11 | 2018-04-10 | Rna for treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909520VA true SG11201909520VA (en) | 2019-11-28 |
Family
ID=58632945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909520V SG11201909520VA (en) | 2017-04-11 | 2018-04-10 | Rna for treatment of autoimmune diseases |
| SG10202111163VA SG10202111163VA (en) | 2017-04-11 | 2018-04-10 | Rna for treatment of autoimmune diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111163VA SG10202111163VA (en) | 2017-04-11 | 2018-04-10 | Rna for treatment of autoimmune diseases |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11701413B2 (en) |
| EP (2) | EP3981424A1 (en) |
| JP (3) | JP7078641B2 (en) |
| KR (2) | KR20190134765A (en) |
| CN (2) | CN118161602A (en) |
| AU (1) | AU2018253352A1 (en) |
| BR (1) | BR112019020667A8 (en) |
| CA (1) | CA3059505A1 (en) |
| CY (1) | CY1124767T1 (en) |
| DK (1) | DK3609529T3 (en) |
| ES (1) | ES2893451T3 (en) |
| HR (1) | HRP20211559T1 (en) |
| HU (1) | HUE056871T2 (en) |
| IL (2) | IL269793B (en) |
| LT (1) | LT3609529T (en) |
| MX (1) | MX2019012144A (en) |
| PL (1) | PL3609529T3 (en) |
| PT (1) | PT3609529T (en) |
| RS (1) | RS62582B1 (en) |
| SG (2) | SG11201909520VA (en) |
| SI (1) | SI3609529T1 (en) |
| WO (2) | WO2018188730A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3880174A2 (en) * | 2018-11-12 | 2021-09-22 | Translate Bio, Inc. | Methods for inducing immune tolerance |
| US11161892B1 (en) | 2020-12-07 | 2021-11-02 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN115232825B (en) * | 2021-04-22 | 2023-09-26 | 中国人民解放军军事科学院军事医学研究院 | New coronavirus vaccine based on 1083 skeleton |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| WO2022248525A1 (en) | 2021-05-26 | 2022-12-01 | Imcyse Sa | Methods of treating or preventing autoimmune diseases |
| AR126654A1 (en) | 2021-06-29 | 2023-11-01 | Imcyse Sa | PEPTIDES AND METHODS FOR THE TREATMENT OF OPTICAL NEUROMYELITIS |
| CN113336862B (en) * | 2021-07-05 | 2022-03-01 | 广东省科学院动物研究所 | Recombinant protein for resisting multiple sclerosis and preparation method and application thereof |
| WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
| WO2023131254A1 (en) * | 2022-01-06 | 2023-07-13 | 上海吉量医药工程有限公司 | Pseudouridine modified at n1 position and use thereof in mrna synthesis |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030098B2 (en) * | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
| AU2002952834A0 (en) | 2002-09-16 | 2002-12-05 | The Walter And Eliza Hall Institute Of Medical Research | A method of treating an autoimmune disease |
| ES2735531T3 (en) | 2005-08-23 | 2019-12-19 | Univ Pennsylvania | RNA containing modified nucleosides and methods of use thereof |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EP2050814A1 (en) | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
| EP3623474A1 (en) * | 2009-12-07 | 2020-03-18 | The Trustees of The University of Pennsylvania | Rna preparations comprising purified modified rna for reprogramming cells |
| US9778250B2 (en) * | 2011-05-10 | 2017-10-03 | The Brigham And Women's Hospital, Inc. | Detecting inclusion body myositis |
| WO2013044419A1 (en) * | 2011-09-30 | 2013-04-04 | Beijing Advaccine Biotechnology Co., Ltd. | Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases |
| EP4372081A2 (en) | 2011-12-30 | 2024-05-22 | Cellscript, Llc | Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
| US20180303925A1 (en) | 2015-04-27 | 2018-10-25 | The Trustees Of The University Of Pennsylvania | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response |
| CN106395552B (en) | 2015-08-03 | 2020-03-17 | 奥的斯电梯公司 | Cordless elevator system guide rail assembly |
| AU2016315444B2 (en) * | 2015-08-28 | 2023-02-23 | BioNTech SE | Method for reducing immunogenicity of RNA |
| AU2017251983B2 (en) | 2016-04-22 | 2023-07-20 | BioNTech SE | Methods for providing single-stranded RNA |
-
2017
- 2017-04-11 WO PCT/EP2017/058651 patent/WO2018188730A1/en active Application Filing
-
2018
- 2018-04-10 ES ES18717580T patent/ES2893451T3/en active Active
- 2018-04-10 MX MX2019012144A patent/MX2019012144A/en unknown
- 2018-04-10 BR BR112019020667A patent/BR112019020667A8/en unknown
- 2018-04-10 SG SG11201909520V patent/SG11201909520VA/en unknown
- 2018-04-10 US US16/500,005 patent/US11701413B2/en active Active
- 2018-04-10 HU HUE18717580A patent/HUE056871T2/en unknown
- 2018-04-10 EP EP21191317.3A patent/EP3981424A1/en active Pending
- 2018-04-10 JP JP2019555957A patent/JP7078641B2/en active Active
- 2018-04-10 KR KR1020197033154A patent/KR20190134765A/en not_active Application Discontinuation
- 2018-04-10 CN CN202410206779.6A patent/CN118161602A/en active Pending
- 2018-04-10 KR KR1020247008874A patent/KR20240042138A/en active Search and Examination
- 2018-04-10 EP EP18717580.7A patent/EP3609529B1/en active Active
- 2018-04-10 DK DK18717580.7T patent/DK3609529T3/en active
- 2018-04-10 SI SI201830424T patent/SI3609529T1/en unknown
- 2018-04-10 PT PT187175807T patent/PT3609529T/en unknown
- 2018-04-10 HR HRP20211559TT patent/HRP20211559T1/en unknown
- 2018-04-10 RS RS20211224A patent/RS62582B1/en unknown
- 2018-04-10 PL PL18717580T patent/PL3609529T3/en unknown
- 2018-04-10 SG SG10202111163VA patent/SG10202111163VA/en unknown
- 2018-04-10 CA CA3059505A patent/CA3059505A1/en active Pending
- 2018-04-10 LT LTEPPCT/EP2018/059188T patent/LT3609529T/en unknown
- 2018-04-10 CN CN201880024391.7A patent/CN110719787B/en active Active
- 2018-04-10 AU AU2018253352A patent/AU2018253352A1/en active Pending
- 2018-04-10 WO PCT/EP2018/059188 patent/WO2018189193A1/en unknown
-
2019
- 2019-10-03 IL IL269793A patent/IL269793B/en unknown
-
2021
- 2021-10-06 CY CY20211100867T patent/CY1124767T1/en unknown
-
2022
- 2022-02-28 IL IL290980A patent/IL290980A/en unknown
- 2022-05-19 JP JP2022082384A patent/JP7444924B2/en active Active
-
2023
- 2023-06-12 US US18/333,273 patent/US20230330198A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025246A patent/JP2024059794A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909520VA (en) | Rna for treatment of autoimmune diseases | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201408261UA (en) | Syringe | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201809341PA (en) | Mobile robot | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201909003YA (en) | Integrated vascular access device and anchor pad | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201808829VA (en) | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201909856XA (en) | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression | |
| SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents |